Single dose primaquine has no effect on paracetamol clearance

Area of Science:

• Pharmacology
• Drug Metabolism
• Clinical Pharmacology

Background:

• Paracetamol (acetaminophen) is a widely used analgesic and antipyretic.
• Primaquine is an antimalarial drug known to affect certain oxidative metabolic pathways.
• Understanding potential drug-drug interactions is crucial for patient safety.

Purpose of the Study:

• To investigate the effect of a single therapeutic dose of primaquine on the pharmacokinetic profile of paracetamol.
• To evaluate the impact of primaquine on paracetamol's metabolic pathways, specifically conjugation and oxidation.

Main Methods:

• A pharmacokinetic study was conducted in 6 healthy volunteers.
• Paracetamol metabolism was assessed before and during co-administration of a 45 mg dose of primaquine.
• Analysis included evaluation of paracetamol glucuronide, paracetamol sulphate, paracetamol cysteine, and paracetamol mercapturate formation.

Main Results:

• Primaquine did not alter the kinetics of paracetamol.
• No significant effect of primaquine was observed on the conjugation pathways (glucuronidation and sulfation) of paracetamol.
• Primaquine did not inhibit the oxidative metabolism of paracetamol, as indicated by metabolite levels.

Conclusions:

• Therapeutic doses of primaquine do not interfere with the metabolism of paracetamol in healthy individuals.
• The findings suggest that co-administration of paracetamol and primaquine is unlikely to result in altered paracetamol exposure due to metabolic interactions.
• Primaquine's inhibitory effect on oxidative metabolism, observed with other drugs like antipyrine, does not extend to paracetamol.